Comparative Pharmacology
Head-to-head clinical analysis: KLONOPIN RAPIDLY DISINTEGRATING versus MENRIUM 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLONOPIN RAPIDLY DISINTEGRATING versus MENRIUM 5 2.
KLONOPIN RAPIDLY DISINTEGRATING vs MENRIUM 5-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Combination of chlordiazepoxide (benzodiazepine) potentiating GABA-A receptor activity, and clidinium (antimuscarinic) blocking muscarinic acetylcholine receptors.
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
1 tablet orally every 6-8 hours as needed for anxiety, up to 4 tablets per day. Each tablet contains chlordiazepoxide 5 mg and clidinium bromide 2.5 mg.
None Documented
None Documented
Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Chlordiazepoxide: 5-30 hours (increases with age, hepatic impairment); Clidinium: 8-12 hours
Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Chlordiazepoxide: 90-96% renal as metabolites, <5% unchanged; Clidinium: 70-80% fecal, 10-20% renal as metabolites
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination